Dec 19 (Reuters) - PTC Therapeutics Inc PTCT.O:
PTC THERAPEUTICS ANNOUNCES VATIQUINONE NDA SUBMISSION TO FDA FOR THE TREATMENT OF CHILDREN AND ADULTS LIVING WITH FRIEDREICH ATAXIA
PTC'S FOURTH APPROVAL APPLICATION SUBMITTED TO FDA IN 2024
Source text: ID:nPn8CvJfqa
Further company coverage: PTCT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.